BACKGROUND: UDP-glucuronosyltransferase (UGT) 2B17 is a phase II metabolizing enzyme that mediates the glucuronidation of C(19) steroids. A deletion polymorphism in the UGT2B17 gene is associated with a substantial reduction in glucuronidation activity in vitro. METHODS: We examined the association between the UGT2B17 deletion polymorphism and the risk of incident prostate cancer in a population-based study from central Arkansas that included 411 Caucasian cases and 397 Caucasian controls. We developed a novel high-throughput procedure that uses real-time PCR and allelic discrimination for genotyping analysis. RESULTS: The prevalence of the UGT2B17 deletion [(0/0)] was 12% in the controls, which was consistent with previous population estimates and with Hardy Weinberg equilibrium. There was no association between the UGT2B17 deletion polymorphism and prostate cancer risk in unconditional logistic regression analysis. Compared to the wild-type group (+/+), the adjusted odds ratio (OR) was 0.89 (95% CI=0.55-1.45) for the homozygous deletion (0/0), and the OR was 0.99 (95% CI=0.73-1.35) for the heterozygote group (+/0). CONCLUSION: These findings show that the UGT2B17 deletion polymorphism is not associated with prostate cancer risk in Caucasians.
BACKGROUND:UDP-glucuronosyltransferase (UGT) 2B17 is a phase II metabolizing enzyme that mediates the glucuronidation of C(19) steroids. A deletion polymorphism in the UGT2B17 gene is associated with a substantial reduction in glucuronidation activity in vitro. METHODS: We examined the association between the UGT2B17 deletion polymorphism and the risk of incident prostate cancer in a population-based study from central Arkansas that included 411 Caucasian cases and 397 Caucasian controls. We developed a novel high-throughput procedure that uses real-time PCR and allelic discrimination for genotyping analysis. RESULTS: The prevalence of the UGT2B17 deletion [(0/0)] was 12% in the controls, which was consistent with previous population estimates and with Hardy Weinberg equilibrium. There was no association between the UGT2B17 deletion polymorphism and prostate cancer risk in unconditional logistic regression analysis. Compared to the wild-type group (+/+), the adjusted odds ratio (OR) was 0.89 (95% CI=0.55-1.45) for the homozygous deletion (0/0), and the OR was 0.99 (95% CI=0.73-1.35) for the heterozygote group (+/0). CONCLUSION: These findings show that the UGT2B17 deletion polymorphism is not associated with prostate cancer risk in Caucasians.
Authors: Andrea Gsur; Martin Preyer; Gerald Haidinger; Georg Schatzl; Stephan Madersbacher; Michael Marberger; Christian Vutuc; Michael Micksche Journal: Cancer Epidemiol Biomarkers Prev Date: 2002-05 Impact factor: 4.254
Authors: Jong Park; Lan Chen; Kristin Shade; Philip Lazarus; John Seigne; Stephen Patterson; Mohamed Helal; Julio Pow-Sang Journal: J Urol Date: 2004-06 Impact factor: 7.450
Authors: Delores J Grant; Cathrine Hoyo; Shannon D Oliver; Leah Gerber; Katie Shuler; Elizabeth Calloway; Alexis R Gaines; Megan McPhail; Jonathan N Livingston; Ricardo M Richardson; Joellen M Schildkraut; Stephen J Freedland Journal: Genet Test Mol Biomarkers Date: 2012-10-25
Authors: Yali Xue; Donglin Sun; Allan Daly; Fengtang Yang; Xue Zhou; Mengyao Zhao; Ni Huang; Tatiana Zerjal; Charles Lee; Nigel P Carter; Matthew E Hurles; Chris Tyler-Smith Journal: Am J Hum Genet Date: 2008-08-28 Impact factor: 11.025
Authors: Shanly M Chen; Daniel H Atchley; Michael A Murphy; Bill J Gurley; Landry K Kamdem Journal: J Clin Pharmacol Date: 2015-12-31 Impact factor: 3.126
Authors: Andrea Y Angstadt; Terryl J Hartman; Samuel M Lesko; Joshua E Muscat; Junjia Zhu; Carla J Gallagher; Philip Lazarus Journal: Genes Chromosomes Cancer Date: 2014-06 Impact factor: 5.006
Authors: Xi He; Leah M Hesse; Suwagmani Hazarika; Gina Masse; Jerold S Harmatz; David J Greenblatt; Michael H Court Journal: Br J Clin Pharmacol Date: 2009-11 Impact factor: 4.335